Needham & Company LLC Reaffirms “Buy” Rating for TScan Therapeutics (NASDAQ:TCRX)

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “buy” rating reissued by Needham & Company LLC in a research report issued on Tuesday,Benzinga reports. They presently have a $11.00 price target on the stock. Needham & Company LLC’s target price indicates a potential upside of 109.52% from the company’s current price.

Several other equities research analysts have also recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a research report on Tuesday, August 13th. Wedbush reissued an “outperform” rating and set a $10.00 price target on shares of TScan Therapeutics in a research report on Tuesday, November 5th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, TScan Therapeutics presently has an average rating of “Buy” and an average target price of $12.00.

TScan Therapeutics Price Performance

Shares of TScan Therapeutics stock opened at $5.25 on Tuesday. TScan Therapeutics has a 52-week low of $3.73 and a 52-week high of $9.69. The stock has a market capitalization of $278.09 million, a price-to-earnings ratio of -4.95 and a beta of 0.79. The company has a fifty day moving average of $5.34 and a 200-day moving average of $6.52. The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.77 and a current ratio of 7.77.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.02. The business had revenue of $0.54 million during the quarter, compared to analysts’ expectations of $1.55 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 63.11%. Equities research analysts expect that TScan Therapeutics will post -1.17 EPS for the current year.

Insiders Place Their Bets

In related news, Director Barbara Klencke acquired 5,000 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was acquired at an average cost of $5.53 per share, for a total transaction of $27,650.00. Following the acquisition, the director now owns 40,000 shares of the company’s stock, valued at $221,200. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. In other TScan Therapeutics news, Director Barbara Klencke purchased 5,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was bought at an average cost of $5.53 per share, for a total transaction of $27,650.00. Following the purchase, the director now directly owns 40,000 shares in the company, valued at $221,200. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Zoran Zdraveski sold 164,686 shares of the stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $5.78, for a total transaction of $951,885.08. Following the completion of the transaction, the insider now owns 4,716 shares of the company’s stock, valued at approximately $27,258.48. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders purchased 15,000 shares of company stock worth $82,550. 2.76% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Tocqueville Asset Management L.P. bought a new stake in TScan Therapeutics during the 1st quarter valued at about $1,685,000. Bank of Montreal Can bought a new stake in TScan Therapeutics during the 2nd quarter valued at about $749,000. Bank of New York Mellon Corp bought a new stake in TScan Therapeutics during the 2nd quarter valued at about $682,000. Great Point Partners LLC bought a new stake in TScan Therapeutics during the 2nd quarter valued at about $5,504,000. Finally, Marshall Wace LLP increased its stake in TScan Therapeutics by 60.8% during the 2nd quarter. Marshall Wace LLP now owns 307,487 shares of the company’s stock valued at $1,799,000 after purchasing an additional 116,316 shares in the last quarter. 82.83% of the stock is currently owned by institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.